Empagliflozin and Dapagliflozin Outcomes in Heart Failure

Are the clinical outcomes of dapagliflozin and empagliflozin comparable among patients with heart failure (HF) across the full spectrum of ejection fraction in a multicenter clinical setting?In this cohort study of 4930 patients with HF, dapagliflozin and empagliflozin showed no significant difference in the composite outcome of cardiovascular death or HF hospitalization, regardless of left ventricular ejection fraction, over a 16-month follow-up period.These findings suggest that dapagliflozin and empagliflozin offer comparable effectiveness in the management of HF in routine clinical practice; further research is necessary to validate these findings.

Corresponding Author: Hyo-Suk Ahn, MD, PhD, Division of Cardiology, Department of Internal Medicine, Uijeongbu St Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea (alaco0502@gmail.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.